The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
about
Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.Liposomal Doxorubicin in the treatment of breast cancer patients: a reviewImaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots.
P2860
The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@ast
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@en
type
label
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@ast
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@en
prefLabel
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@ast
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@en
P1433
P1476
The use of liposomal anticance ...... ng multidrug resistance (MDR).
@en
P2093
P304
P407
P577
1999-07-01T00:00:00Z